Checkpoint Therapeutics
CKPT
CKPT was delisted on the 29th of May, 2025.
70 hedge funds and large institutions have $50.6M invested in Checkpoint Therapeutics in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 27 increasing their positions, 17 reducing their positions, and 8 closing their positions.
300% more call options, than puts
Call options by funds: $4K | Put options by funds: $1K
100% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 8
65% more capital invested
Capital invested by funds: $30.7M → $50.6M (+$19.9M)
59% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 17
13% more funds holding
Funds holding: 62 → 70 (+8)
0.4% more ownership
Funds ownership: 1.98% → 2.38% (+0.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$9.81M |
| 2 |
JSMC
Jess S. Morgan & Co
Los Angeles,
California
|
+$2M |
| 3 |
SAG
Spotlight Asset Group
Oakbrook Terrace,
Illinois
|
+$1.92M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.36M |
| 5 |
BlackRock
New York
|
+$1.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$1.69M |
| 2 |
Millennium Management
New York
|
-$862K |
| 3 |
Morgan Stanley
New York
|
-$389K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$294K |
| 5 |
Legal & General Group
London,
United Kingdom
|
-$148K |
CKPT Hedge Fund Activity: Q1 2021 in Review
70 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Checkpoint Therapeutics (CKPT) for Q1 2021, worth a combined $50.6M — up 65% from $30.7M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new CKPT positions and 8 closed out — a net gain of 8 holders — while 27 added to existing stakes and 17 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $9.81M. The largest seller was CVI Holdings, exiting entirely with an estimated $1.69M sold.
- 70 institutional investors held Checkpoint Therapeutics (CKPT) as of Q1 2021, up from 62 in Q4 2020.
- Funds reported $50.6M of Checkpoint Therapeutics stock for Q1 2021, up 65% quarter-over-quarter.
- 16 funds opened new Checkpoint Therapeutics positions in Q1 2021 and 8 closed out, a net change of +8 holders.
- The largest Checkpoint Therapeutics buyer in Q1 2021 was Opaleye Management, an estimated $9.81M added.
- The largest Checkpoint Therapeutics seller in Q1 2021 was CVI Holdings, an estimated $1.69M sold.
Based on aggregated 13F filings for Q1 2021.